Ipsen Articles
Ipsen/Octagen's OBI-1 to enter Ph II testing
22 November 2004
Ipsen pursues drug specialization strategy
14 June 2004
French pharma heads form defense group
3 May 2004
Auxilium and Ipsen sign Testim agreement
12 April 2004
University of Bath awarded L4.16 million research grant
29 March 2004
Ipsen links with Pfizer in breast cancer trials
29 March 2004
Ipsen buys UK firm Sterix
8 March 2004
Roche acquires rights to Ipsen's BIM 51077
27 October 2003
Ipsen and Octagen start Ph I for OBI-1
15 September 2003
French Council halts 10 drugs' support cuts
4 August 2003
Ipsen in product deal with Japan's Teijin
14 July 2003
Modest growth for Ipsen in 2002
2 June 2003
Ipsen to develop Spirogen's cancer drug
2 June 2003
Beaufour Ipsen to sell valsartan in France
19 May 2003
Beaufour Ipsen promotes Christophe Jean
19 May 2003
Beaufour gets EU Ok for Nutropin AQ
24 March 2003
Lunbeck acquires Synaptic in $122M deal
17 March 2003
Lunbeck acquires Synaptic in $122M deal
17 March 2003
Beaufour names Claire Giraut CFO
10 February 2003
Ipsen, Inamed start Ph II botulinum toxin study
13 January 2003
GAEBE names board members
8 July 2002
Beaufour Ipsen net profit up 22.6%
3 June 2002
Beaufour Ipsen signs inflammation R&D deal
18 March 2002
Beafour signs two product development deals
11 February 2002
Ipsen launches depot lanreotide in UK.
21 January 2002
Corixa and Beaufour Ipsen deal on AnergiX.MG tech.
21 January 2002
New CEO at Beaufour-Ipsen
6 December 2001
French drug spending plan nears completion
16 May 2001
French drug spending plan nears completion
14 May 2001
Beaufour-Ipsen to list by 2003
21 November 2000
Elan's NeuroBloc backed by CPMP
6 November 2000
Pierre Fabre merging with bioMerieux to create France's top independent
22 September 2000
SNIP names new vice president
14 September 2000
Israel's Medison sets up JV with AltaRex
12 July 2000
France delays drug de-reimbursements
10 July 2000
Beuafour Ipsen to work on molecular identity of tumors
18 April 2000
Board changes at the SNIP
13 April 2000
French studies differ on vasodilators' value
3 April 2000
French govt sets sights on 148 "dubious" drug products for cuts
23 November 1999
French drug price cuts hit mainly smaller cos
11 October 1999
SMEs: a role model for EU candidate countries
6 July 1999
BI and QLT terminate Photofrin contract
1 July 1999
Novartis Compares Growth Hormone Therapies
17 June 1999
Ipsen drugs show early promise in diabetes
28 April 1999
Elan posts strong first quarter sales growth
26 April 1999
Torii licenses Somatuline in Japan
14 January 1999
Paribas Investing In Euro Pharma
17 November 1998
Beaufour Ipsen and Octagen collaborate
29 October 1998
Beaufour Ipsen Outlines Growth Strategy to 2000
7 October 1998
Russian Non-Rx-Bound Sales Growth To 2005
1 May 1998
Speywood Pharma Changes Name
26 March 1998
FDA Clears QLT's PhotoFrin For Lung Cancer
15 January 1998
First Corlopam Launch Due In USA On January 1
11 December 1997
EFPIA Expands Membership To Drugmakers
24 November 1997
Positive Phase III Data On Dusa's Levulan
29 October 1997
Growing Foreign Presence In China's Pharma Industry
22 September 1997
Photofrin Approved In Germany; Fall Launch
14 August 1997
Synthelabo Denies French Targets For Acquisition
21 April 1997
French Pharma Industry Aims To Double China Sales
26 March 1997
Beaufour Ipsen Reshaping For Future Growth
3 March 1997
Beaufour Ipsen And QLT In European Licensing Deal
6 January 1997
QLT Signs Photofrin Deal With Beaufour Ipsen
23 December 1996
French Generic Market "Still Weak And Patchy"
16 December 1996
Theratechnologies Secures TH-9506 Partner
28 October 1996
Neurex Licenses Corlopam To French Firm
7 October 1996
Expansia's Investment Program
12 August 1996
NCEs In 1995: A Good Range Of Novel Drugs
29 January 1996
US Bioscience Signs Euro Marketing Deal
17 July 1995
Beaufour Ipsen: Paxeladine
15 May 1995
Oligopoly The Future For The Pharma Industry
2 January 1995
Restructuring Message For French Drug Industry
19 December 1994
Beaufour Ipsen To Acquire Porton Int'l
31 October 1994
BEAUFOUR-IPSEN SET ON INDEPENDENCE
6 July 1992
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
